Sling Therapeutics, Inc.

Potential competitors to Amgen’s Tepezza (teprotumumab), the only approved drug therapy for thyroid eye disease (TED), keep lining up as privately held Sling Therapeutics unveiled positive Phase IIb/I

Viridian Therapeutics, Inc. ’s anti-IGF-1R monoclonal antibody candidate, VRDN-001, has garnered attention after promising proof-of-concept data in chronic thyroid eye disease (TED) but not all of it

The number of biopharmaceutical companies raising venture capital this year has far outpaced the number raising money in public offerings, with 126 venture rounds during the first quarter versus just